A new bill led by Democrats, the Medicare Cost Cap Act, would create a $5,000 cap on out-of-pocket costs for traditional Medicare beneficiaries. The proposal would significantly alter patient spending dynamics for covered services under traditional Medicare. While GLP-1 coverage policy and affordability remain central to beneficiary decision-making, the Cost Cap Act shifts the discussion toward downstream utilization and the political economy of healthcare spending. For biopharma stakeholders, out-of-pocket changes can influence demand and access patterns for branded medicines, especially where coverage and patient cost-sharing determine whether therapies are started and sustained.